第8巻 2012年12月　第4号

■論説

がん治療と緩和ケア（4）―分子標的治療薬の薬剤経済分析
稲毛　俊介, 伊勢　雄也, 片山　志郎
日本医科大学付属病院薬剤部

Treatment of Cancer and Palliative Care (4) Cost-effectiveness Analysis of Molecularly Targeted Drugs
Shunsuke Inage, Yuya Ise and Shirou Katayama
Department of Pharmaceutical Service, Nippon Medical School

Various molecularly targeted drugs are now in clinical use in Japan. These agents are generally more effective than previous drugs but are more expensive. Several recent studies have examined the cost-effectiveness of using molecularly targeted drugs in cancer treatment. Herein, we discuss reports about the use of trastuzumab for early-stage breast cancer, lapatinib for advanced breast cancer, and bevacizumab for advanced non-small cell lung cancer.

日医大医会誌 2012; 8(4), 241-245

Key words
cost-effectiveness analysis, pharmacoeconomics, molecularly targeted drugs, treatment of cancer

Correspondence to
Shunsuke Inage, Department of Pharmaceutical Service, Nippon Medical School Hospital, 1-1-5 Sendagi, Bunkyo-ku Tokyo 113-8603, Japan
E-mail：shunsukeinage@nms.ac.jp

受付：2012年4月6日　受理：2012年7月24日